Serum neurofilament light as biomarker of seizure‐related neuronal injury in status epilepticus
Biomarkers of neuronal damage in status epilepticus (SE) would be of great relevance for clinical and research purposes. In a retrospective cross‐sectional study, serum neurofilament light chain (NfL) levels were measured in patients with SE (30 subjects), patients with drug‐resistant epilepsy (30 s...
Gespeichert in:
| Veröffentlicht in: | Epilepsia (Copenhagen) 2022-01, Vol.63 (1), p.e23-e29 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e29 |
|---|---|
| container_issue | 1 |
| container_start_page | e23 |
| container_title | Epilepsia (Copenhagen) |
| container_volume | 63 |
| creator | Giovannini, Giada Bedin, Roberta Ferraro, Diana Vaudano, Anna Elisabetta Mandrioli, Jessica Meletti, Stefano |
| description | Biomarkers of neuronal damage in status epilepticus (SE) would be of great relevance for clinical and research purposes. In a retrospective cross‐sectional study, serum neurofilament light chain (NfL) levels were measured in patients with SE (30 subjects), patients with drug‐resistant epilepsy (30 subjects), and healthy controls (30 subjects). Serum NfL levels were higher in patients with SE (median = 26.15 pg/ml) compared to both epilepsy patients (median = 7.35 pg/ml) and healthy controls (median = 6.81 pg/ml; p |
| doi_str_mv | 10.1111/epi.17132 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9299158</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2600820410</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4432-798eaabb34ee641f5a47c357420dd2e069ab0dedb1f934a306efbc5215eac3da3</originalsourceid><addsrcrecordid>eNp1kc1u1TAQhS1ERS8XFrwAssQGFmn9FzvZIFVVC5UqFQlYW5Nk0vqSxBc7prpd9RF4Rp4El5QKkPBmFv7m6Mw5hLzg7IDnd4hbd8ANl-IRWfFSVAXn2jwmK8a4LOqyYvvkaYwbxpjRRj4h-1JVTHOjVwQ-YkgjnTAF37sBRpxmOrjLq5lCpI3zI4QvGKjvaUR3kwL-uP0ecIAZu2VrgoG6aZPCLg8aZ5hTpNnRgNvZtSk-I3s9DBGf3881-Xx68un4fXF-8e7s-Oi8aJWSojB1hQBNIxWiVrwvQZlWlkYJ1nUCma6hYR12De9rqUAyjX3TloKXCK3sQK7J20V3m5oRuzYfEmCw2-DyCTvrwdm_fyZ3ZS_9N1uLuuZllQVe3wsE_zVhnO3oYovDABP6FK3QjFWCKc4y-uofdONTyEncUTlXXZsc_Zq8Wag2-BgD9g9mOLN3xdkck_1VXGZf_un-gfzdVAYOF-A6J7v7v5I9-XC2SP4EMZKmQg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2617669701</pqid></control><display><type>article</type><title>Serum neurofilament light as biomarker of seizure‐related neuronal injury in status epilepticus</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Giovannini, Giada ; Bedin, Roberta ; Ferraro, Diana ; Vaudano, Anna Elisabetta ; Mandrioli, Jessica ; Meletti, Stefano</creator><creatorcontrib>Giovannini, Giada ; Bedin, Roberta ; Ferraro, Diana ; Vaudano, Anna Elisabetta ; Mandrioli, Jessica ; Meletti, Stefano</creatorcontrib><description>Biomarkers of neuronal damage in status epilepticus (SE) would be of great relevance for clinical and research purposes. In a retrospective cross‐sectional study, serum neurofilament light chain (NfL) levels were measured in patients with SE (30 subjects), patients with drug‐resistant epilepsy (30 subjects), and healthy controls (30 subjects). Serum NfL levels were higher in patients with SE (median = 26.15 pg/ml) compared to both epilepsy patients (median = 7.35 pg/ml) and healthy controls (median = 6.81 pg/ml; p < .001). In patients with SE, serum NfL levels showed a high correlation with cerebrospinal fluid (CSF) NfL (τ = .68, p < .001) as well as with CSF total tau (t‐tau) levels (τ = .627, p < .001); they were higher in SE lasting >24 h (p = .013), in refractory/superrefractory SE (p = .004), and in patients who died within 30 days or who presented a worsening of clinical conditions (p = .001). Values of >28.8 pg/ml predicted 30‐day clinical worsening or death (odds ratio [OR] = 10.83, 95% confidence interval [CI] = 1.96–59.83, p = .006) and SE refractoriness (OR = 9.33, 95% CI = 1.51–57.65, p = .016). In conclusion, serum NfL levels are increased in SE and correlate with SE treatment response, duration, and outcomes, therefore representing a promising biomarker of seizure‐related neuronal damage.</description><identifier>ISSN: 0013-9580</identifier><identifier>EISSN: 1528-1167</identifier><identifier>DOI: 10.1111/epi.17132</identifier><identifier>PMID: 34806176</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Biomarkers ; Brief Communication ; Cerebrospinal fluid ; Convulsions & seizures ; Cross-Sectional Studies ; Epilepsy ; Humans ; Intermediate Filaments ; Neurofilament Proteins ; neurofilaments ; Patients ; Retrospective Studies ; Seizures ; Status Epilepticus ; Tau protein</subject><ispartof>Epilepsia (Copenhagen), 2022-01, Vol.63 (1), p.e23-e29</ispartof><rights>2021 The Authors. published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.</rights><rights>2021 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.</rights><rights>2021. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4432-798eaabb34ee641f5a47c357420dd2e069ab0dedb1f934a306efbc5215eac3da3</citedby><cites>FETCH-LOGICAL-c4432-798eaabb34ee641f5a47c357420dd2e069ab0dedb1f934a306efbc5215eac3da3</cites><orcidid>0000-0002-3585-5872 ; 0000-0003-4818-3806 ; 0000-0002-6280-7526 ; 0000-0003-0334-539X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fepi.17132$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fepi.17132$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34806176$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Giovannini, Giada</creatorcontrib><creatorcontrib>Bedin, Roberta</creatorcontrib><creatorcontrib>Ferraro, Diana</creatorcontrib><creatorcontrib>Vaudano, Anna Elisabetta</creatorcontrib><creatorcontrib>Mandrioli, Jessica</creatorcontrib><creatorcontrib>Meletti, Stefano</creatorcontrib><title>Serum neurofilament light as biomarker of seizure‐related neuronal injury in status epilepticus</title><title>Epilepsia (Copenhagen)</title><addtitle>Epilepsia</addtitle><description>Biomarkers of neuronal damage in status epilepticus (SE) would be of great relevance for clinical and research purposes. In a retrospective cross‐sectional study, serum neurofilament light chain (NfL) levels were measured in patients with SE (30 subjects), patients with drug‐resistant epilepsy (30 subjects), and healthy controls (30 subjects). Serum NfL levels were higher in patients with SE (median = 26.15 pg/ml) compared to both epilepsy patients (median = 7.35 pg/ml) and healthy controls (median = 6.81 pg/ml; p < .001). In patients with SE, serum NfL levels showed a high correlation with cerebrospinal fluid (CSF) NfL (τ = .68, p < .001) as well as with CSF total tau (t‐tau) levels (τ = .627, p < .001); they were higher in SE lasting >24 h (p = .013), in refractory/superrefractory SE (p = .004), and in patients who died within 30 days or who presented a worsening of clinical conditions (p = .001). Values of >28.8 pg/ml predicted 30‐day clinical worsening or death (odds ratio [OR] = 10.83, 95% confidence interval [CI] = 1.96–59.83, p = .006) and SE refractoriness (OR = 9.33, 95% CI = 1.51–57.65, p = .016). In conclusion, serum NfL levels are increased in SE and correlate with SE treatment response, duration, and outcomes, therefore representing a promising biomarker of seizure‐related neuronal damage.</description><subject>Biomarkers</subject><subject>Brief Communication</subject><subject>Cerebrospinal fluid</subject><subject>Convulsions & seizures</subject><subject>Cross-Sectional Studies</subject><subject>Epilepsy</subject><subject>Humans</subject><subject>Intermediate Filaments</subject><subject>Neurofilament Proteins</subject><subject>neurofilaments</subject><subject>Patients</subject><subject>Retrospective Studies</subject><subject>Seizures</subject><subject>Status Epilepticus</subject><subject>Tau protein</subject><issn>0013-9580</issn><issn>1528-1167</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNp1kc1u1TAQhS1ERS8XFrwAssQGFmn9FzvZIFVVC5UqFQlYW5Nk0vqSxBc7prpd9RF4Rp4El5QKkPBmFv7m6Mw5hLzg7IDnd4hbd8ANl-IRWfFSVAXn2jwmK8a4LOqyYvvkaYwbxpjRRj4h-1JVTHOjVwQ-YkgjnTAF37sBRpxmOrjLq5lCpI3zI4QvGKjvaUR3kwL-uP0ecIAZu2VrgoG6aZPCLg8aZ5hTpNnRgNvZtSk-I3s9DBGf3881-Xx68un4fXF-8e7s-Oi8aJWSojB1hQBNIxWiVrwvQZlWlkYJ1nUCma6hYR12De9rqUAyjX3TloKXCK3sQK7J20V3m5oRuzYfEmCw2-DyCTvrwdm_fyZ3ZS_9N1uLuuZllQVe3wsE_zVhnO3oYovDABP6FK3QjFWCKc4y-uofdONTyEncUTlXXZsc_Zq8Wag2-BgD9g9mOLN3xdkck_1VXGZf_un-gfzdVAYOF-A6J7v7v5I9-XC2SP4EMZKmQg</recordid><startdate>202201</startdate><enddate>202201</enddate><creator>Giovannini, Giada</creator><creator>Bedin, Roberta</creator><creator>Ferraro, Diana</creator><creator>Vaudano, Anna Elisabetta</creator><creator>Mandrioli, Jessica</creator><creator>Meletti, Stefano</creator><general>Wiley Subscription Services, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3585-5872</orcidid><orcidid>https://orcid.org/0000-0003-4818-3806</orcidid><orcidid>https://orcid.org/0000-0002-6280-7526</orcidid><orcidid>https://orcid.org/0000-0003-0334-539X</orcidid></search><sort><creationdate>202201</creationdate><title>Serum neurofilament light as biomarker of seizure‐related neuronal injury in status epilepticus</title><author>Giovannini, Giada ; Bedin, Roberta ; Ferraro, Diana ; Vaudano, Anna Elisabetta ; Mandrioli, Jessica ; Meletti, Stefano</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4432-798eaabb34ee641f5a47c357420dd2e069ab0dedb1f934a306efbc5215eac3da3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Biomarkers</topic><topic>Brief Communication</topic><topic>Cerebrospinal fluid</topic><topic>Convulsions & seizures</topic><topic>Cross-Sectional Studies</topic><topic>Epilepsy</topic><topic>Humans</topic><topic>Intermediate Filaments</topic><topic>Neurofilament Proteins</topic><topic>neurofilaments</topic><topic>Patients</topic><topic>Retrospective Studies</topic><topic>Seizures</topic><topic>Status Epilepticus</topic><topic>Tau protein</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Giovannini, Giada</creatorcontrib><creatorcontrib>Bedin, Roberta</creatorcontrib><creatorcontrib>Ferraro, Diana</creatorcontrib><creatorcontrib>Vaudano, Anna Elisabetta</creatorcontrib><creatorcontrib>Mandrioli, Jessica</creatorcontrib><creatorcontrib>Meletti, Stefano</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Epilepsia (Copenhagen)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Giovannini, Giada</au><au>Bedin, Roberta</au><au>Ferraro, Diana</au><au>Vaudano, Anna Elisabetta</au><au>Mandrioli, Jessica</au><au>Meletti, Stefano</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum neurofilament light as biomarker of seizure‐related neuronal injury in status epilepticus</atitle><jtitle>Epilepsia (Copenhagen)</jtitle><addtitle>Epilepsia</addtitle><date>2022-01</date><risdate>2022</risdate><volume>63</volume><issue>1</issue><spage>e23</spage><epage>e29</epage><pages>e23-e29</pages><issn>0013-9580</issn><eissn>1528-1167</eissn><abstract>Biomarkers of neuronal damage in status epilepticus (SE) would be of great relevance for clinical and research purposes. In a retrospective cross‐sectional study, serum neurofilament light chain (NfL) levels were measured in patients with SE (30 subjects), patients with drug‐resistant epilepsy (30 subjects), and healthy controls (30 subjects). Serum NfL levels were higher in patients with SE (median = 26.15 pg/ml) compared to both epilepsy patients (median = 7.35 pg/ml) and healthy controls (median = 6.81 pg/ml; p < .001). In patients with SE, serum NfL levels showed a high correlation with cerebrospinal fluid (CSF) NfL (τ = .68, p < .001) as well as with CSF total tau (t‐tau) levels (τ = .627, p < .001); they were higher in SE lasting >24 h (p = .013), in refractory/superrefractory SE (p = .004), and in patients who died within 30 days or who presented a worsening of clinical conditions (p = .001). Values of >28.8 pg/ml predicted 30‐day clinical worsening or death (odds ratio [OR] = 10.83, 95% confidence interval [CI] = 1.96–59.83, p = .006) and SE refractoriness (OR = 9.33, 95% CI = 1.51–57.65, p = .016). In conclusion, serum NfL levels are increased in SE and correlate with SE treatment response, duration, and outcomes, therefore representing a promising biomarker of seizure‐related neuronal damage.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>34806176</pmid><doi>10.1111/epi.17132</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-3585-5872</orcidid><orcidid>https://orcid.org/0000-0003-4818-3806</orcidid><orcidid>https://orcid.org/0000-0002-6280-7526</orcidid><orcidid>https://orcid.org/0000-0003-0334-539X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0013-9580 |
| ispartof | Epilepsia (Copenhagen), 2022-01, Vol.63 (1), p.e23-e29 |
| issn | 0013-9580 1528-1167 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9299158 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Biomarkers Brief Communication Cerebrospinal fluid Convulsions & seizures Cross-Sectional Studies Epilepsy Humans Intermediate Filaments Neurofilament Proteins neurofilaments Patients Retrospective Studies Seizures Status Epilepticus Tau protein |
| title | Serum neurofilament light as biomarker of seizure‐related neuronal injury in status epilepticus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T23%3A41%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20neurofilament%20light%20as%20biomarker%20of%20seizure%E2%80%90related%20neuronal%20injury%20in%20status%20epilepticus&rft.jtitle=Epilepsia%20(Copenhagen)&rft.au=Giovannini,%20Giada&rft.date=2022-01&rft.volume=63&rft.issue=1&rft.spage=e23&rft.epage=e29&rft.pages=e23-e29&rft.issn=0013-9580&rft.eissn=1528-1167&rft_id=info:doi/10.1111/epi.17132&rft_dat=%3Cproquest_pubme%3E2600820410%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2617669701&rft_id=info:pmid/34806176&rfr_iscdi=true |